Applications

1207 – Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

-

Service or technology in this application

BRAF V600 mutation testing for locally advanced unresectable stage III or IV melanoma to determine eligibility for access to dabrafenib (co-dependent technology).

Medical condition this application addresses

Melanoma in its advanced form has a poor prognosis. It is increasing in incidence in Australia and globally, and occurs when mutations accumulate in the melanocytes of the skin, mainly as a result of exposure to ultra-violet radiation from sunlight. When mutations accumulate they can eventually deregulate growth and cell cycle control genes, and to lead to tumour formation through proliferation and metastasis of cells.

Application documents

Meetings to consider this application

  • PASC meeting: 
    • 1 to 2 December 2012
    • 12 to 13 April 2012
  • ESC meeting: 
    • 13 to 14 June 2013
  • MSAC meeting: 
    • 5 April 2013
    • 1 August 2013
    • 24-25 November 2016